HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease.

AbstractOBJECTIVES:
Evaluate the prevalence, incidence and impact on prognosis of existing and new onset atrial fibrillation (AF) in patients with stable, symptomatic coronary artery disease.
DESIGN:
Data from the 7 665 participants included in the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) trial was used.
RESULTS:
Over a mean follow-up of 4.9 years, the incidence of recurrent AF in patients with AF at baseline (4.1%) was 13.5/100 patient-years and 1.64/100 patient-years for patients without baseline AF. Patients with AF at baseline had increased mortality and new overt heart failure. New onset AF was associated with increased morbidity and mortality and in particular soon after onset. [adjusted 30-day relative risk for mortality 23, 95% CI 14-36; for debilitating stroke 37, 95% CI 18-77; and for heart failure 54, 95% CI 32-93]. The incidence of AF was not affected by treatment with nifedipine GITS.
CONCLUSION:
The presence of AF in patients with stable symptomatic CAD is an independent risk factor and in particular in the first 30 days for subsequent mortality and morbidity.
AuthorsJan Erik Otterstad, Bridget-Anne Kirwan, Jacobus Lubsen, Sophie De Brouwer, Keith A A Fox, Pernille Corell, Philip A Poole-Wilson, Action Investigators
JournalScandinavian cardiovascular journal : SCJ (Scand Cardiovasc J) Vol. 40 Issue 3 Pg. 152-9 (Jun 2006) ISSN: 1401-7431 [Print] England
PMID16798662 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Calcium Channel Blockers
  • Nifedipine
Topics
  • Aged
  • Atrial Fibrillation (complications, epidemiology, prevention & control)
  • Calcium Channel Blockers (therapeutic use)
  • Coronary Artery Disease (complications, diagnosis, drug therapy)
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Nifedipine (therapeutic use)
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: